PaulGRichardsonMD

Oncology • Boston, MA

Hematologic Oncology

Associate Professor, Medicine, Brigham & Women's Hospital, Harvard Medical School

Join to view full profile

Dr. Richardson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Richardson's full profile

Already have an account?

Office
44 Binney St
# Dana
Boston, MA 02115
Phone+1 617-632-2104

Fax+1 617-632-6624

Education & Training

UMass Chan - BaystateFellowship, Hematology and Medical Oncology, 1991 - 1994
Charing Cross and Westminister Medical SchoolClass of 1986

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 1993 - 2026
CT State Medical License 2022 - 2025

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Boston Magazine Castle Connolly, 2010-2013
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

High-dose ICE With Amifostine Start of enrollment: 1998 Jul 01
Completed
Phase 2
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation Start of enrollment: 2000 Apr 01
Completed
Phase 2
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma Start of enrollment: 2005 Jun 01
Completed
Phase 1
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma Start of enrollment: 2003 Dec 01
Completed
Phase 2
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2004 Aug 01
Completed
Phase 1
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients Start of enrollment: 2006 Jul 01
Completed
Phase 3
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma Start of enrollment: 2005 Dec 01
Completed
Phase 2
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2006 Sep 01
Active, not recruiting
Phase 1, Phase 2
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma Start of enrollment: 2006 Aug 01
Completed
Phase 2
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients Start of enrollment: 2006 Aug 01
Completed
Phase 1, Phase 2
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma Start of enrollment: 2005 Apr 01
Completed
Phase 1
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study Start of enrollment: 2007 Dec 01
Completed
Phase 3
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients Start of enrollment: 2009 Dec 01
Terminated
Phase 3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2012 Jan 01
Completed
Phase 1
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma Start of enrollment: 2012 Mar 01
Unknown status
Phase 1, Phase 2
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma Start of enrollment: 2012 Nov 01
Completed
Phase 1
Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator Start of enrollment: 2013 Jun 24
Completed
Phase 2
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 1, Phase 2
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2016 Dec 28
Completed
Phase 2
Ixazomib + Pomalidomide + Dexamethasone In MM Start of enrollment: 2019 Sep 18
Recruiting
Phase 1, Phase 2
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma Start of enrollment: 2020 Aug 17
Suspended
Phase 1, Phase 2
Defibrotide for the Treatment of Severe COVID-19 Start of enrollment: 2021 Jan 01
Recruiting
Phase 2
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2021 Nov 11
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
Blood Advances. 2024-12-03
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
Paul G Richardson, Aurore Perrot, Joseph Mikhael, Thomas Martin, Meral Beksac
Blood Cancer Journal. 2024-11-28
Editorial Expression of Concern: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma ce...
Constantine S Mitsiades, Nicholas Mitsiades, Vassiliki Poulaki, Robert Schlossman, Masaharu Akiyama
Oncogene. 2024-11-11

Journal Articles

APRIL Signaling via TACI Mediates Immunosuppression by T Regulatory Cells in Multiple Myeloma: Therapeutic Implications
Kenneth C Anderson, Nikhil Munshi, Paul Richardson, Chirag Acharya, Nature
Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
How I Treat the Young Patient with Multiple Myeloma
Paul Richardson, MD, Blood

Abstracts/Posters

High-Dimensional Heterogeneity of Waldenstr_m Macroglobulinemia within Its Immune Tumor Microenvironment
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 ...
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 ...
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and In...
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory ...
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myeloma Heterogeneity within Its Complex Immune Ecosystem
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 S...
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma
Paul G. Richardson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Basel...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Current Obstacles in Myeloma Management: Debating the Evidence
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 S...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in ...
2019 ASCO Annual Meeting - 6/1/2019
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).
2019 ASCO Annual Meeting - 6/1/2019
The Evolution of Multiple Myeloma Patient Management: Managing Today and Preparing for Tomorrow
60th American Society of Hematology Annual Meeting - 11/30/2018
Pomalidomide (POM), bortezomib, and low dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relap...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Join now to see all

Press Mentions

Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
Why Breakthrough COVID Deaths Can Be MisunderstoodOctober 18th, 2021
$Analyzing Survival Outcomes with Ixazomib-Rd in Relapsed/Refractory Multiple Myeloma$
Analyzing Survival Outcomes with Ixazomib-Rd in Relapsed/Refractory Multiple MyelomaAugust 2nd, 2021
Join now to see all